

Annex A

Table 1 – Scenarios & implications for range of potential AMC support to India (estimated)

Scenario	% of AMC support to India ¹	# doses to India ²	Funding to India ³	% India population covered ⁴	% AMC91 population covered ⁵
Low end of range	10%	~95 - 125 million	~US\$ 665 million	~3-5%	~17-22%
High end of range	20%	~190 - 250 million	~US\$ 1.3 billion	~7-9%	~15-20%
Pro-rata (for reference only)	35%	~330 - 440 million	~US\$ 2.3 billion	~12-16%	~12-16%

Table 2 – Allocation of US\$ 150 million in delivery support (CCE and TA) to AMC91

Current Scenario	Amount Allocated
Cold Chain Equipment	US\$ 50 million
Technical Support	US\$ 60 million
CCE Reserve (e.g. UCC Support)	US\$ 10 million
Total Allocated	US\$ 120 million
Amount held pending India COVAX AMC Board decision	US\$ 30 million

Low range scenario US\$ 15 million (10% of total allocation)	High range scenario US\$ 30 million (20% of total allocation)
Currently estimated Govt needs for TA above US\$ 27 million for preparedness, planning and delivering for COVID-19 vaccine rollout	The Government of India has already submitted its needs for urgent TA and CCE surpassing the maximum envelope. The Government has already mobilised funds domestically to supplement CCE, but gaps remain.
Allocating US\$ 15 million would not allow for urgent gap filling of TA or CCE needs	Allocating US\$ 30 million would allow for similar pro rata allocation of prioritised AMC56

¹ AMC donor-funded doses, and implied estimated funds (actual funding amount will depend on dose price). Does not account for cost-sharing. Does not include Buffer.

² Ranges based on base case and higher price resource mobilization scenarios, as presented in Paper 8.

³ Assumes indicative average fully loaded price of US\$ 5.2 - 7 per dose, plus compensation scheme estimated at US\$0.10/dose. Actual price, and thus amount of funding allocated, will vary based on available technologies.

⁴ Assumes 2 dose regimen.

⁵ Assumes 2 dose regimen.